<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font3" size="8" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font4" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font5" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font6" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font7" size="8" family="AkzidenzGroteskBE" color="#ffffff"/>
<text top="42" left="57" width="88" height="7" font="font0" id="p1_t1" reading_order_no="1" segment_no="0" tag_type="title"><b>Breast Cancer Research</b></text>
<text top="42" left="145" width="90" height="7" font="font1" id="p1_t2" reading_order_no="2" segment_no="0" tag_type="title">    Vol 7 No 6    Reis-Filho </text>
<text top="42" left="234" width="16" height="7" font="font2" id="p1_t3" reading_order_no="3" segment_no="0" tag_type="title"><i>et al.</i></text>
<text top="735" left="18" width="23" height="8" font="font3" id="p1_t4" reading_order_no="0" segment_no="6" tag_type="text">R1033</text>
<text top="555" left="57" width="240" height="9" font="font4" id="p1_t5" reading_order_no="10" segment_no="3" tag_type="text">showed no amplification. EGFR activating mutations have</text>
<text top="567" left="57" width="240" height="9" font="font4" id="p1_t6" reading_order_no="11" segment_no="3" tag_type="text">been described in lung cancer and in brain tumours, but these</text>
<text top="579" left="57" width="240" height="9" font="font4" id="p1_t7" reading_order_no="12" segment_no="3" tag_type="text">mutations have proven extremely rare in other types of cancer,</text>
<text top="590" left="57" width="240" height="9" font="font4" id="p1_t8" reading_order_no="13" segment_no="3" tag_type="text">including breast carcin<a href="">omas [8,37]. Howev</a>er, Weber and</text>
<text top="602" left="57" width="240" height="9" font="font4" id="p1_t9" reading_order_no="14" segment_no="3" tag_type="text">coworker<a href="">s [38] rec</a>ently described EGFR missense mutations</text>
<text top="614" left="57" width="95" height="9" font="font4" id="p1_t10" reading_order_no="15" segment_no="3" tag_type="text">in sporadic and familial (</text>
<text top="614" left="152" width="31" height="9" font="font5" id="p1_t11" reading_order_no="16" segment_no="3" tag_type="text"><i>BRCA1</i></text>
<text top="614" left="183" width="3" height="9" font="font4" id="p1_t12" reading_order_no="17" segment_no="3" tag_type="text">/</text>
<text top="614" left="186" width="34" height="9" font="font5" id="p1_t13" reading_order_no="18" segment_no="3" tag_type="text"><i>BRCA2 </i></text>
<text top="614" left="221" width="77" height="9" font="font4" id="p1_t14" reading_order_no="19" segment_no="3" tag_type="text">related) breast can-</text>
<text top="626" left="57" width="240" height="9" font="font4" id="p1_t15" reading_order_no="20" segment_no="3" tag_type="text">cer and demonstrated that these mutations are significantly</text>
<text top="637" left="57" width="216" height="9" font="font4" id="p1_t16" reading_order_no="21" segment_no="3" tag_type="text">more frequent in the latter. Therefore, further analysis of </text>
<text top="637" left="273" width="24" height="9" font="font5" id="p1_t17" reading_order_no="22" segment_no="3" tag_type="text"><i>EGFR</i></text>
<text top="649" left="57" width="240" height="9" font="font4" id="p1_t18" reading_order_no="23" segment_no="3" tag_type="text">gene sequence in MBCs may explain the overexpression of</text>
<text top="661" left="57" width="116" height="9" font="font4" id="p1_t19" reading_order_no="24" segment_no="3" tag_type="text">EGFR in those cases lacking </text>
<text top="661" left="173" width="24" height="9" font="font5" id="p1_t20" reading_order_no="25" segment_no="3" tag_type="text"><i>EGFR</i></text>
<text top="661" left="197" width="54" height="9" font="font4" id="p1_t21" reading_order_no="26" segment_no="3" tag_type="text"> amplification.</text>
<text top="684" left="57" width="240" height="9" font="font4" id="p1_t22" reading_order_no="27" segment_no="5" tag_type="text">An alternative mechanism for EGFR expression in MBC may</text>
<text top="696" left="57" width="240" height="9" font="font4" id="p1_t23" reading_order_no="28" segment_no="5" tag_type="text">be maintenance of a myoepithelial/basal phenotype. In fact,</text>
<text top="708" left="57" width="240" height="9" font="font4" id="p1_t24" reading_order_no="29" segment_no="5" tag_type="text">expression of EGFR is part of the definition of 'basal-like'</text>
<text top="720" left="57" width="240" height="9" font="font4" id="p1_t25" reading_order_no="30" segment_no="5" tag_type="text">tumours proposed by Nielsen and coworkers <a href="">[39]. E</a>GFR is</text>
<text top="555" left="315" width="241" height="9" font="font4" id="p1_t26" reading_order_no="31" segment_no="4" tag_type="text">consistently expressed in myoepithelial cells of the <a href="">breast [40].</a></text>
<text top="567" left="315" width="240" height="9" font="font4" id="p1_t27" reading_order_no="32" segment_no="4" tag_type="text"><a href="">We [26,41,42] and others [30,31,43-45] have </a>demonstrated</text>
<text top="579" left="315" width="240" height="9" font="font4" id="p1_t28" reading_order_no="33" segment_no="4" tag_type="text">that the vast majority of MBCs consistently express basal/</text>
<text top="590" left="315" width="240" height="9" font="font4" id="p1_t29" reading_order_no="34" segment_no="4" tag_type="text">myoepithelial markers. Furthermore, indirect evidence from a</text>
<text top="602" left="315" width="240" height="9" font="font4" id="p1_t30" reading_order_no="35" segment_no="4" tag_type="text">study using murine cell lines suggests that transformed</text>
<text top="614" left="315" width="240" height="9" font="font4" id="p1_t31" reading_order_no="36" segment_no="4" tag_type="text">myoepithelial cells may give rise to tumours with sarcomatous</text>
<text top="626" left="315" width="240" height="9" font="font4" id="p1_t32" reading_order_no="37" segment_no="4" tag_type="text">and carcinosarcomatous patterns, similar to those observed in</text>
<text top="637" left="315" width="240" height="9" font="font4" id="p1_t33" reading_order_no="38" segment_no="4" tag_type="text">spindle cell carcinomas and carcinomas with heterologous</text>
<text top="649" left="315" width="241" height="9" font="font4" id="p1_t34" reading_order_no="39" segment_no="4" tag_type="text">elements [<a href="">46]</a>. Therefore, one could speculate that overex-</text>
<text top="661" left="315" width="240" height="9" font="font4" id="p1_t35" reading_order_no="40" segment_no="4" tag_type="text">pression of EGFR, without gene amplification, could simply</text>
<text top="673" left="315" width="240" height="9" font="font4" id="p1_t36" reading_order_no="41" segment_no="4" tag_type="text">reflect maintenance of the basal-like/myoepithelial phenotype</text>
<text top="684" left="315" width="216" height="9" font="font4" id="p1_t37" reading_order_no="42" segment_no="4" tag_type="text">of these lesions. Conversely, one cannot rule out that </text>
<text top="684" left="531" width="24" height="9" font="font5" id="p1_t38" reading_order_no="43" segment_no="4" tag_type="text"><i>EGFR</i></text>
<text top="696" left="315" width="241" height="9" font="font4" id="p1_t39" reading_order_no="44" segment_no="4" tag_type="text">gene amplification is one of the genetic mechanisms whereby</text>
<text top="708" left="315" width="240" height="9" font="font4" id="p1_t40" reading_order_no="45" segment_no="4" tag_type="text">basal/myoepithelial differentiation pathways are activated in</text>
<text top="720" left="315" width="136" height="9" font="font4" id="p1_t41" reading_order_no="46" segment_no="4" tag_type="text">transformed luminal epithelial cells.</text>
<text top="85" left="57" width="31" height="7" font="font6" id="p1_t42" reading_order_no="4" segment_no="1" tag_type="title"><b>Figure 3</b></text>
<text top="524" left="57" width="256" height="7" font="font7" id="p1_t43" reading_order_no="5" segment_no="2" tag_type="text">EGFR overexpression and amplification: prognostic impact on DFS and OS</text>
<text top="524" left="57" width="330" height="7" font="font1" id="p1_t44" reading_order_no="6" segment_no="2" tag_type="text">EGFR overexpression and amplification: prognostic impact on DFS and OS. CISH, chromogenic </text>
<text top="524" left="386" width="23" height="7" font="font2" id="p1_t45" reading_order_no="7" segment_no="2" tag_type="text"><i>in situ </i></text>
<text top="524" left="409" width="139" height="7" font="font1" id="p1_t46" reading_order_no="8" segment_no="2" tag_type="text">hybridization; DFS, disease-free survival; </text>
<text top="533" left="57" width="207" height="7" font="font1" id="p1_t47" reading_order_no="9" segment_no="2" tag_type="text">EGFR, epidermal growth factor receptor; OS, overall survival.</text>
</page>
</pdf2xml>
